汇宇制药12月23日获融资买入482.31万元，融资余额2.64亿元

Group 1 - The core viewpoint of the news is that Huayu Pharmaceutical's stock experienced a decline of 1.47% on December 23, with a trading volume of 46.703 million yuan, indicating a potential concern in market sentiment towards the company [1] - As of December 23, Huayu Pharmaceutical had a total margin trading balance of 264 million yuan, with a financing net purchase of 214,400 yuan on that day, suggesting a high level of investor interest despite the stock price drop [1] - The company primarily focuses on the research, production, and sales of oncology drugs and complex injectable drugs, with 97.27% of its revenue coming from drug sales [1] Group 2 - As of September 30, the number of shareholders for Huayu Pharmaceutical decreased by 14.45% to 13,900, while the average circulating shares per person increased by 16.89% to 24,700 shares [2] - For the period from January to September 2025, Huayu Pharmaceutical reported a revenue of 742 million yuan, a year-on-year decrease of 12.92%, and a net profit attributable to shareholders of -50.8047 million yuan, reflecting a significant decline of 122.35% [2] - The company has distributed a total of 474 million yuan in dividends since its A-share listing, with 385 million yuan distributed over the past three years [2]